The Future of Pharmacoepidemiology

Pharmacoepidemiology, Fifth Edition

Volumn , Issue , 2012, Pages 893-903

  Strom, Brian L ^a   Kimmel, Stephen E ^a   Hennessy, Sean ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Adverse drug effect; Drug approval; Drug crisis; Drug evaluation; Safety

Indexed keywords

EID: 84888735361     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781119959946.ch48     Document Type: Chapter

References (29)

1. Andrews EB, Avorn J, Bortnichak EA, Chen R, Dai WS, Dieck GS, et al. Guidelines for Good Epidemiology Practices for Drug, Device, and Vaccine Research in the United States . Pharmacoepidemiol Drug Saf 1996; 5: 333-8.
2. ISPE. Guidelines for good pharmacoepidemiology practices (GPP) . Pharmacoepidemiol Drug Saf 2008; 17: 200-8.
3. Strom BL, West SL, Sim E, Carson JL. The epidemiology of the acute flank pain syndrome from suprofen . Clin Pharmacol Ther 1989; 46: 693-9.
4. Spielberg SP. Idiosyncratic drug reactions: interaction of development and genetics . Semin Perinatol 1992; 16: 58-62.
5. Woosley RL, Drayer DE, Reidenberg MM, Nies AS, Carr K, Oates JA. Effect of acetylator phenotype on the rate at which procainamide induces antinuclear antibodies and the lupus syndrome . N Engl J Med 1978; 298: 1157-9.
6. Leeder JS, Riley RJ, Cook VA , Spielberg SP. Human anti-cytochrome P450 antibodies in aromatic anticonvulsant-induced hypersensitivity reactions . J Pharmacol Exp Ther 1992; 263: 360-7.
7. Bray J, Sludden J, Griffin MJ, Cole M, Verrill M, Jamieson D, et al. Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide . Br J Cancer 2010; 102: 1003-9.
8. Schmeling H, Biber D, Heins S, Horneff G. Influence of methylenetetrahydrofolate reductase polymorphisms on efficacy and toxicity of methotrexate in patients with juvenile idiopathic arthritis . J Rheumatol 2005; 32: 1832-6.
9. Tassaneeyakul W, Jantararoungtong T, Chen P, Lin PY , Tiamkao S, Khunarkornsiri U, et al. Strong association between HLA -B*5801 and allopurinol -induced Stevens -Johnson syndrome and toxic epidermal necrolysis in a Thai population . Pharmacogenet Genomics 2009; 19: 704-9.
10. Strom BL, Gibson GA. A systematic integrated approach to improving drug prescribing in an acute care hospital: A potential model for applied hospital pharmacoepidemiology . Clin Pharmacol Ther 1993; 54: 126-33.
11. Classen DC, Pestotnik SL, Evans RS, Burke JP . Computerized surveillance of adverse drug events in hospital patients . JAMA 1991; 266: 2847-51.
12. Bates DW , Leape LL, Cullen DJ, Laird N, Petersen LA, Teich JM, et al. Effect of computerized physician order entry and a team intervention on prevention of serious medication errors . JAMA 1998; 280: 1311-6.
13. Pullar T, Feely M. Problems of compliance with drug treatment: new solutions? Pharm J 1990; 245: 213-5.
14. Urquhart J. The electronic medication event monitor-lessons for pharmacotherapy . Clin Pharmacokinet 1997; 32: 345-56.
15. Joellenbeck LM, Zwanziger LL, Durch JS, Strom BL, eds. The Anthrax Vaccine: Is It Safe? Does It Work? National Academy Press , 2002.
16. Committee on Smallpox Vaccination Program Implementation, Board on Health Promotion and Disease Prevention; Baciu A, Anason AP , Stratton K, Strom B (eds). The Smallpox Vaccination Program: Public Health in an Age of Terrorism.Washington, DC: National Academies Press , 2005.
17. Strom BL, Carson JL, Use of automated databases for pharmacoepidemiology research . Epidemiol Rev 1990; 12: 87-107.
18. General Accountability Office . Testimony Before the Special Committee on Aging, US Senate. Medicare Part D: Spending, Beneficiary Out - of - Pocket Costs, and Efforts to Obtain Price Concessions for Certain High - cost Drugs, GAO-10-529T. March 17, 2010. http://www.gao.gov/ new.items/d10529t.pdf(accessed July 2011).
19. The Food and Drug Administration, eHealth Foundation, and the Brookings Institute . Sentinel Initiative: Structure, Function and Scope. Washington, D.C., December 16, 2008. http://www.fda.gov/oc/initiatives/ criticalpath/transcript121608.pdf(accessed July 2011).
20. [2008] Annual Report of the Boards of Trustees of the Federal Hospital Insurance and Federal Supplementary Medical Insurance Trust Funds. http://www.cms.hhs.gov/ ReportsTrustFunds/downloads/tr2008.pdf(accessed July 2011).
21. Yudkin JS. The economics of pharmaceutical supply in Tanzania . Int J Health Serv 1980; 10: 455-77.
22. Yudkin JS. Use and misuse of drugs in the Third World . Dan Med Bull 1984; 31 Suppl 1: 11-7.
23. Lunde PKM. WHO's programme on essential drugs. Background, implementation, present state and prospectives. Dan Med Bull 1984; 31 ( Suppl 1 ): 23-7.
24. Howard NJ, Laing RO. Changes in the World Health Organization essential drug list . Lancet 1991; 338: 743-5.
25. Young FE. The role of the FDA in the effort against AIDS. Public Health Rep 1988; 103: 242-5.
26. Joint Commission on Prescription Drug Use . 1980 Report of the Joint Commission on Prescription Drug Use . KF3869.R4. Rockville, MD.
27. Furberg CD, Levin AA, Gross PA , Shapiro RS, Strom BL. The FDA and drug safety: a proposal for sweeping changes. Arch Intern Med 2006; 166: 1938-42.
28. Wood AJ, Stein CM, Woosley R. Making medicines safer-the need for an independent drug safety board . N Engl J Med 1998; 339: 1851-4.
29. Moore TJ, Psaty BM, Furberg CD. Time to act on drug safety . JAMA 1998; 279: 1571-3.